The Health and Human Services Department announced Thursday that California-Based Gilead Sciences Inc. has agreed to donate medications that reduce the risk of HIV transmission for up to 200,000 people a year.
Truvada is the only drug that is approved for pre-exposure prophylaxis (PrEP), a treatment that, if administered daily, is at least 90 percent effective in HIV prevention, according to the Centers for Disease Control and Prevention.More news: Supreme Court allows lawsuit over iPhone apps
In 2013, more than 39,000 people were infected by the HIV virus.
It was announced on Thursday (May 9) that pre-exposure prophylaxis (PrEP) drug Truvada will be made available for free for almost a quarter of a million people in the United States for 11 years.More news: Ireland Bans US Hate Pastor, First Ban Under 1999 Act
"This agreement will help close that gap substantially and deliver on President Trump's promise to end the HIV epidemic in America". This will allow an additional 200,000 people to have access to the drug. The drug, despite being manufactured at a relatively low price, can cost a user up to $2,000 for one month's supply. Worldwide, there were about 1.8 million new cases of HIV in 2017.
Carl Schmid, AIDS Institute deputy executive director, welcomed the donation from Gilead, stating that it would free up federal government spending that would otherwise be used on getting medication of uninsured people. However, the House Appropriations Committee has approved almost $500 million in spending for disease treatment and prevention earlier this week.More news: Kabir Singh Trailer Reaction | Shahid Kapoor, Kiara Advani | Sandeep Reddy Vanga